InteliSwab
Device
OraSure Technologies Inc.
Total Payments
$1.6M
Transactions
134
Doctors
13
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $325,056 | 68 | 13 |
| 2022 | $1.2M | 66 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 89 | 86.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $180,469 | 10 | 11.6% |
| Consulting Fee | $26,382 | 13 | 1.7% |
| Travel and Lodging | $4,345 | 11 | 0.3% |
| Food and Beverage | $216.22 | 11 | 0.0% |
Payments by Type
Research
$1.3M
89 transactions
General
$211,411
45 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter Study Conducted to Evaluate the Performance of the InteliSwab COVID-19 Rapid Test | OraSure Technologies Inc. | $910,807 | 0 |
| InteliSwab COVID-19 Rapid Test Clinical Evaluation Study in Asymptomatic Individuals | OraSure Technologies Inc. | $185,310 | 0 |
| Sample Acquisition Protocol for Development of Tests to Detect Antigens or Antibodies to Coronavirus | OraSure Technologies Inc. | $125,582 | 0 |
| Human Factors and Clinical Validation of the OraSure Technologies InteliSwab COVID-19 + FLU A&B Rapid Test in Anterior Nares Nasal Samples for Over-the-Counter (OTC) Use | OraSure Technologies Inc. | $94,875 | 0 |
| A Clinical Study Conducted to Evaluate the Performance of the InteliSwab COVID-19 Rapid Test | OraSure Technologies Inc. | $15,770 | 0 |
| A Multicenter Study Conducted to Evaluate the Performance of the COVID-19 Self-Test | OraSure Technologies Inc. | $13,000 | 0 |
| Reproducibility of the InteliSwab COVID-19 Rapid Test Site Selection Letter | OraSure Technologies Inc. | $3,000 | 0 |
Top Doctors Receiving Payments for InteliSwab
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sunrise, FL | $1.4M | 91 |
| , MD | Internal Medicine | Gladwyne, PA | $92,885 | 15 |
| , MD | Internal Medicine | Charlestown, MA | $91,364 | 13 |
| , M.D | Infectious Disease | Seattle, WA | $18,029 | 5 |
| , M.D | Emergency Medicine | Jackson, MS | $1,000 | 1 |
| , MD | Family Medicine | Baltimore, MD | $26.11 | 1 |
| , DO | Student in an Organized Health Care Education/Training Program | Rockville, MD | $26.10 | 1 |
| , CRNP, FNP | Family | Rockville, MD | $26.10 | 1 |
| , MD | Pulmonary Disease | Baltimore, MD | $26.10 | 1 |
| , DDS | Dentist | Jackson, MS | $19.05 | 1 |
| , APRN, PMHNP-BC | Psychiatric/Mental Health | Daytona Beach, FL | $15.29 | 1 |
| Mikala Hughes | Nurse Practitioner | Daytona Beach, FL | $15.28 | 1 |
| , MSN, APRN, FNP-C | Family | Longwood, FL | $15.28 | 1 |
| , MD | Emergency Medicine | Wharton, NJ | $13.22 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $1.6M
- Total Doctors 13
- Transactions 134
About InteliSwab
InteliSwab is a device associated with $1.6M in payments to 13 healthcare providers, recorded across 134 transactions in the CMS Open Payments database. The primary manufacturer is OraSure Technologies Inc..
Payment data is available from 2022 to 2024. In 2024, $325,056 was paid across 68 transactions to 13 doctors.
The most common payment nature for InteliSwab is "Unspecified" ($1.3M, 86.4% of total).
InteliSwab is associated with 7 research studies, including "A Multicenter Study Conducted to Evaluate the Performance of the InteliSwab COVID-19 Rapid Test" ($910,807).